Clementia Pharmaceuticals is a technology company.
Clementia Pharmaceuticals has raised $93.0M across 3 funding rounds.
Key people at Clementia Pharmaceuticals.
Clementia Pharmaceuticals has raised $93.0M in total across 3 funding rounds.
Key people at Clementia Pharmaceuticals.
Clementia Pharmaceuticals has raised $93.0M in total across 3 funding rounds.
Clementia Pharmaceuticals's investors include Amplitude VC, Mott Family Capital, OrbiMed, Soffinova Partners.
Clementia Pharmaceuticals was a clinical-stage biopharmaceutical company developing innovative therapies for ultra-rare bone disorders, particularly fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), conditions with no approved treatments at the time.[1][3][4] Its lead product, palovarotene—a selective retinoic acid receptor gamma (RARγ) agonist—targeted heterotopic ossification (HO) associated with FOP flare-ups, serving patients with these high-unmet-need diseases by aiming to prevent debilitating bone formation.[1][2] The company built momentum through late-stage trials and planned a 2019 FDA NDA submission but was acquired by Ipsen in 2019 for its rare disease portfolio, ceasing independent operations.[1][2]
Founded around 2012–2014 (based on SEC filings and early venture backing), Clementia emerged from the need for treatments in rare bone disorders, backed by investors like BDC Capital's Healthcare Venture Fund and Amplitude Venture Capital.[2][6] Key figures included leadership focused on clinical innovation, with early traction from palovarotene's development for FOP—a genetic disorder causing progressive bone formation in soft tissues.[1][6] Pivotal moments included advancing to late-stage trials and the 2019 Ipsen acquisition announcement, which validated its science amid growing rare disease focus.[1]
Clementia rode the rare disease therapeutics trend in biotech, where orphan drug incentives and genetic insights drove investment in ultra-rare conditions like FOP (affecting ~1 in 2 million).[1][6] Timing aligned with 2010s advances in receptor agonists and precision medicine, amplified by market forces like high pricing power for orphan drugs and biopharma acquisitions to bolster portfolios—Ipsen's move exemplified this to expand in rare diseases alongside oncology.[1] It influenced the ecosystem by validating RARγ as a platform for bone disorders, paving the way for Ipsen's continued development and inspiring similar ultra-rare focuses amid rising gene therapy competition.
Post-2019 acquisition, Clementia's assets like palovarotene integrated into Ipsen's rare disease portfolio, likely advancing approvals and commercialization for FOP/MO amid ongoing trials.[1] Trends like AI-driven drug discovery and expanded orphan incentives will shape its legacy, potentially evolving Ipsen's influence in bone therapeutics. Watch for regulatory milestones and expanded indications, tying back to Clementia's core mission of innovating for untreatable disorders.
Clementia Pharmaceuticals has raised $93.0M across 3 funding rounds. Most recently, it raised $60.0M Venture Round in June 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2015 | $60.0M Venture Round | Amplitude VC, Mott Family Capital, OrbiMed, Soffinova Partners | |
| Jan 1, 2015 | $10.0M Series A | Amplitude VC, OrbiMed | |
| Jan 1, 2014 | $23.0M Series A | Amplitude VC, OrbiMed |
